[go: up one dir, main page]

CL2014002668A1 - Método de tratamiento del cáncer que comprende administrar 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7(8h)-ona y n-((s)-2,3-dihidroxipropil)-3-(2-fluoro-4-yodo-fenilamino)isonicotinamida; composicion farmaceutica; uso de una combinacion para tratar cancer tal como cancer de pulmon, cancer de mama triple negativo, entre otros. - Google Patents

Método de tratamiento del cáncer que comprende administrar 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7(8h)-ona y n-((s)-2,3-dihidroxipropil)-3-(2-fluoro-4-yodo-fenilamino)isonicotinamida; composicion farmaceutica; uso de una combinacion para tratar cancer tal como cancer de pulmon, cancer de mama triple negativo, entre otros.

Info

Publication number
CL2014002668A1
CL2014002668A1 CL2014002668A CL2014002668A CL2014002668A1 CL 2014002668 A1 CL2014002668 A1 CL 2014002668A1 CL 2014002668 A CL2014002668 A CL 2014002668A CL 2014002668 A CL2014002668 A CL 2014002668A CL 2014002668 A1 CL2014002668 A1 CL 2014002668A1
Authority
CL
Chile
Prior art keywords
cancer
isonicotinamide
dihydroxypropyl
pyrido
phenylamino
Prior art date
Application number
CL2014002668A
Other languages
English (en)
Inventor
Janet Anne Meurer Ogden
Joanne Lager
Karl Hsu
Original Assignee
Merck Patent Gmbh
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Sanofi Sa filed Critical Merck Patent Gmbh
Publication of CL2014002668A1 publication Critical patent/CL2014002668A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2014002668A 2012-04-06 2014-10-03 Método de tratamiento del cáncer que comprende administrar 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7(8h)-ona y n-((s)-2,3-dihidroxipropil)-3-(2-fluoro-4-yodo-fenilamino)isonicotinamida; composicion farmaceutica; uso de una combinacion para tratar cancer tal como cancer de pulmon, cancer de mama triple negativo, entre otros. CL2014002668A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621252P 2012-04-06 2012-04-06
FR1351158 2013-02-12
US201361771457P 2013-03-01 2013-03-01

Publications (1)

Publication Number Publication Date
CL2014002668A1 true CL2014002668A1 (es) 2015-01-16

Family

ID=49301040

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002668A CL2014002668A1 (es) 2012-04-06 2014-10-03 Método de tratamiento del cáncer que comprende administrar 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7(8h)-ona y n-((s)-2,3-dihidroxipropil)-3-(2-fluoro-4-yodo-fenilamino)isonicotinamida; composicion farmaceutica; uso de una combinacion para tratar cancer tal como cancer de pulmon, cancer de mama triple negativo, entre otros.

Country Status (18)

Country Link
US (1) US20150031882A1 (es)
EP (1) EP2854854A1 (es)
JP (1) JP2015515476A (es)
KR (1) KR20150003786A (es)
CN (1) CN104334192A (es)
AU (1) AU2013243429A1 (es)
CA (1) CA2869152A1 (es)
CL (1) CL2014002668A1 (es)
CO (1) CO7121349A2 (es)
CR (1) CR20140480A (es)
DO (1) DOP2014000221A (es)
EA (1) EA201491836A1 (es)
MX (1) MX2014012001A (es)
PE (1) PE20142020A1 (es)
PH (1) PH12014502219A1 (es)
SG (1) SG11201406199TA (es)
TN (1) TN2014000418A1 (es)
WO (1) WO2013152165A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095829A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors
JP6745048B2 (ja) * 2015-10-14 2020-08-26 日東紡績株式会社 ２種のプロテインキナーゼの活性測定を用いる解析方法による、薬剤感受性ヒト細胞株の判定方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7956191B2 (en) 2004-10-20 2011-06-07 Merck Serono Sa 3-arylamino pyridine derivatives
US8044062B2 (en) * 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
UA116188C2 (uk) 2005-10-07 2018-02-26 Екселіксіс, Інк. Інгібітори фосфатидилінозит-3-кінази і способи їх застосування
US20110086837A1 (en) * 2009-10-12 2011-04-14 Genentech, Inc. Combinations of a pi3k inhibitor and a mek inhibitor
AR084216A1 (es) * 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit

Also Published As

Publication number Publication date
JP2015515476A (ja) 2015-05-28
WO2013152165A1 (en) 2013-10-10
DOP2014000221A (es) 2014-12-15
AU2013243429A1 (en) 2014-10-23
CR20140480A (es) 2014-11-17
MX2014012001A (es) 2015-05-11
PH12014502219A1 (en) 2015-01-12
CN104334192A (zh) 2015-02-04
TN2014000418A1 (en) 2016-03-30
SG11201406199TA (en) 2014-10-30
EA201491836A1 (ru) 2015-02-27
CO7121349A2 (es) 2014-11-20
EP2854854A1 (en) 2015-04-08
US20150031882A1 (en) 2015-01-29
CA2869152A1 (en) 2013-10-10
KR20150003786A (ko) 2015-01-09
PE20142020A1 (es) 2014-12-24

Similar Documents

Publication Publication Date Title
UY35115A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
MX2018005708A (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7.
IL239488A0 (en) A gpc3-targeted medicinal agent for the treatment of patients for whom treatment with a gpc3-targeted medicinal agent is beneficial
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
NZ702663A (en) Nuclear transport modulators and uses thereof
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
MX366899B (es) Nuevos compuestos.
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
IL235593B (en) Factor 4 of a blood platelet that interacts with the parenoid for the treatment of side effects as a result of inhibiting the formation of blood cells due to an antineoplastic treatment regimen in cancer patients
NZ631144A (en) Compositions and methods for transmucosal absorption
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
GB2515439B (en) Vesicular formulations for use in the treatment of reduced mobility
EP3318879A4 (en) Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag
MY180320A (en) Chlorin derivative useful in photodynamic therapy and diagnosis
GB201511770D0 (en) Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
EA201600318A1 (ru) Циклические тиеноурацилкарбоксамиды и их применение
MX2015013155A (es) Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
CL2014002668A1 (es) Método de tratamiento del cáncer que comprende administrar 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7(8h)-ona y n-((s)-2,3-dihidroxipropil)-3-(2-fluoro-4-yodo-fenilamino)isonicotinamida; composicion farmaceutica; uso de una combinacion para tratar cancer tal como cancer de pulmon, cancer de mama triple negativo, entre otros.
CO6731081A2 (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
MX355719B (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.
PT2870164T (pt) Derivados de imidazo[2,1-b]tiazol, as suas preparações e utilização como medicamentos
AR094063A1 (es) Uso de aclidinio, composicion farmaceutica y metodo para mejorar la actividad fisica en pacientes respiratorios
PH12015500070A1 (en) Pediatric oral liquid compositions containing nepadutant
CL2014003072A1 (es) Uso de un compuesto 2-((2r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida (veliparib o abt-888) o de una sal farmaceuticamente aceptable que sirve para el tratamiento de las metástasis en el cerebro con una combinación de una terapia con radiación en la totalidad del cerebro.